128 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
similar to the Services; nor has received any agency letter alleging the same; (v) has not been terminated from any investigation or research project … an approved or pending drug product application; (iii) the subject of an FDA debarment investigation or proceeding (or similar proceeding of a foreign
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
27 Nov 23
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
8:45am
on Employee’s own judgment and investigation in accepting Employee’s employment with the Company, and (iii) Employee has not relied on any
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
authorities outside the United States. Patient enrollment can be affected by many factors, including:
severity of the disease under investigation … ;
availability and efficacy of medications already approved for the disease under investigation;
eligibility criteria for the trial in question
8-K
EX-10.1
zi8fpxqk1q 05o3pr
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-5.1
oxux s83e
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-10.2
b72o2t5zfk26 jx7jev8
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-10.1
grktb kguyyap3
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
8-K
EX-10.1
5e37ivwaauscrhr
23 Jun 21
Entry into a Material Definitive Agreement
4:15pm
424B5
n3w85dp x3dug43tj6
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K/A
EX-1.1
qx007
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K/A
EX-5.1
ijwuc9h
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K/A
EX-10.1
c8e ila4r5b9b81
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-5.1
d4fpinet
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm